Targeting lysyl oxidase (LOX) overcomes chemotherapy resistance in triple negative breast cancer
Open Access
- 15 May 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Nature Communications
- Vol. 11 (1), 1-17
- https://doi.org/10.1038/s41467-020-16199-4
Abstract
Chemoresistance is a major obstacle in triple negative breast cancer (TNBC), the most aggressive breast cancer subtype. Here we identify hypoxia-induced ECM re-modeler, lysyl oxidase (LOX) as a key inducer of chemoresistance by developing chemoresistant TNBC tumors in vivo and characterizing their transcriptomes by RNA-sequencing. Inhibiting LOX reduces collagen cross-linking and fibronectin assembly, increases drug penetration, and downregulates ITGA5/FN1 expression, resulting in inhibition of FAK/Src signaling, induction of apoptosis and re-sensitization to chemotherapy. Similarly, inhibiting FAK/Src results in chemosensitization. These effects are observed in 3D-cultured cell lines, tumor organoids, chemoresistant xenografts, syngeneic tumors and PDX models. Re-expressing the hypoxia-repressed miR-142-3p, which targets HIF1A, LOX and ITGA5, causes further suppression of the HIF-1α/LOX/ITGA5/FN1 axis. Notably, higher LOX, ITGA5, or FN1, or lower miR-142-3p levels are associated with shorter survival in chemotherapy-treated TNBC patients. These results provide strong pre-clinical rationale for developing and testing LOX inhibitors to overcome chemoresistance in TNBC patients.Keywords
Funding Information
- U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (2P20GM109091-06)
- European Molecular Biology Organization (IG-2791)
- American Cancer Society (RSG-19-194-01-CSM, IRG-17-179-04)
- European Commission (PCIG14-GA-2013-631149)
This publication has 70 references indexed in Scilit:
- Integrin α5β1, the Fibronectin Receptor, as a Pertinent Therapeutic Target in Solid TumorsCancers, 2013
- The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroupsNature, 2012
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular MatricesMolecular & Cellular Proteomics, 2012
- Global microRNA level regulation of EGFR‐driven cell‐cycle protein network in breast cancerMolecular Systems Biology, 2012
- Hypoxia-inducible factor 1 is a master regulator of breast cancer metastatic niche formationProceedings of the National Academy of Sciences of the United States of America, 2011
- The Role of Lysyl Oxidase in SRC-Dependent Proliferation and Metastasis of Colorectal CancerJNCI Journal of the National Cancer Institute, 2011
- MicroRNA control of signal transductionNature Reviews Molecular Cell Biology, 2010
- Hypoxia-Induced Lysyl Oxidase Is a Critical Mediator of Bone Marrow Cell Recruitment to Form the Premetastatic NicheCancer Cell, 2009
- How basal are triple‐negative breast cancers?International Journal of Cancer, 2008
- Single-step doxorubicin-selected cancer cells overexpress the ABCG2 drug transporter through epigenetic changesBritish Journal of Cancer, 2008